ClinicalTrials.Veeva

Menu

Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

Hypercholesterolemia

Study type

Observational

Funder types

Industry

Identifiers

NCT00240344
NL401142
REALISTIC

Details and patient eligibility

About

The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) guidelines.

Enrollment

2,650 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • High risk patients
  • High doses of other statins
  • LDL-C known, starts with Crestor 10 mg
  • Permission to use patient data by AstraZeneca (AZ)

Trial contacts and locations

75

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems